Happy Caps Mushroom Home Grow Kits will soon be available in over 135 retail stores across Canada, including Longo's 31...
Dr. Mark Huh recognized for his valued and dedicated teaching by University of Pennsylvania School of Dental MedicineCINNAMINSON, NJ /...
PaxMedica to discuss significance of Phase 3 study resultsInterview to be webcast on Tuesday, August 15, 2023, at 10:30 am...
MVID is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity...
~ Approval of Study Represents Progression Toward Full Phase 3 Evaluation of PF614 ~~ Study to Assess PF614 Time of...
AFTER ACQUIRING ESN GROUP, XCELERATE SIGNS MARKETING AGREEMENTProductSector to Provide Brand Development AssistanceMAULDIN, SC / ACCESSWIRE / August 8, 2023...
LAS VEGAS, NV / ACCESSWIRE / August 8, 2023 / CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), (the ''Company'' or ''CLS''), a...
Funding Accelerates the Development of Compliance Automation SolutionsLOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / LighthouseAI™, an industry...
Second Quarter Revenue Increased 18% to $147 MillionFORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO)...
ANN ARBOR, MI / ACCESSWIRE / August 8, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health...
Net sales for the second quarter of 2023 were $16.1 million, down 7.2%, compared to $17.4 million for the second...
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of...
Advanced panel already generating six-figure pre-ordersNEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc....
Chiesi Group announces mid-year turnover of €1,497 millionSubstantial growth of each of Chiesi’s business areasEurope remains the biggest market, followed...
LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health, a leading provider of Human Understanding® and data-driven insights, is...
– Second quarter revenue of $12.4M, +53% year-over-year growth– Second quarter pulse recurring revenue of $3.3M, +100% year-over-year growth– First...
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across...
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical...
BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected...